Semaglutide News

New GLP-1 pill helps patients lose up to 8% of body weight, trial shows - The Guardian

New GLP-1 pill helps patients lose up to 8% of body weight, trial shows The Guardian

Eli Lilly is set to release a once-daily pill to rival Ozempic this year. People are losing 15 to 20 pounds on it, but there's a catch. - Business Insider

Eli Lilly is set to release a once-daily pill to rival Ozempic this year. People are losing 15 to 20 pounds on it, but there's a catch. Business Insider

Head-to-head trial shows Eli Lilly’s oral GLP-1 orforglipron outperforms oral semaglutide - Yahoo

Head-to-head trial shows Eli Lilly’s oral GLP-1 orforglipron outperforms oral semaglutide Yahoo

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet - Eli Lilly and Company

Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet Eli Lilly and Company

New GLP-1 pill orforglipron outperforms oral semaglutide in yearlong diabetes trial - Medical Xpress

New GLP-1 pill orforglipron outperforms oral semaglutide in yearlong diabetes trial Medical Xpress

Researchers discover benefits of once-a-day weight loss pill - AOL.com

Researchers discover benefits of once-a-day weight loss pill AOL.com

Hidden ingredient in Ozempic and Wegovy tablets raises new gut health questions - ScienceDaily

Hidden ingredient in Ozempic and Wegovy tablets raises new gut health questions ScienceDaily

Another Novo Nordisk class action alleges Ozempic caused vision loss - Class Action Lawsuits

Another Novo Nordisk class action alleges Ozempic caused vision loss Class Action Lawsuits

Abbott seals distribution pact with Novo to market Ozempic second brand in India - ET Pharma

Abbott seals distribution pact with Novo to market Ozempic second brand in India ET Pharma

Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire - NDTV

Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire NDTV

Head-to-head trial pitting Eli Lilly’s oral GLP-1 against oral semaglutide underscores efficacy of weight-loss pills - Scientific American

Head-to-head trial pitting Eli Lilly’s oral GLP-1 against oral semaglutide underscores efficacy of weight-loss pills Scientific American

Oral semaglutide lowers risk of heart failure events in people with Type 2 diabetes - OHSU News

Oral semaglutide lowers risk of heart failure events in people with Type 2 diabetes OHSU News

Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access - PR Newswire

Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access PR Newswire

Orforglipron Outperforms Oral Semaglutide in Head-to-Head T2D Trial - Pharmacy Times

Orforglipron Outperforms Oral Semaglutide in Head-to-Head T2D Trial Pharmacy Times

Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison - Nature

Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison Nature

ACHIEVE-3: Orforglipron Achieves Superiority to Oral Semaglutide in Poorly Controlled T2D - HCPLive

ACHIEVE-3: Orforglipron Achieves Superiority to Oral Semaglutide in Poorly Controlled T2D HCPLive

Oral Semaglutide Pills for Weight Management: What to Know - Cedars-Sinai

Oral Semaglutide Pills for Weight Management: What to Know Cedars-Sinai

Novel GLP-1 Pill Tops Oral Semaglutide for Diabetes - MedPage Today

Novel GLP-1 Pill Tops Oral Semaglutide for Diabetes MedPage Today

Orforglipron is more effective than semaglutide, according to a phase III clinical trial - Science Media Centre España

Orforglipron is more effective than semaglutide, according to a phase III clinical trial Science Media Centre España

Orforglipron Demonstrates Superior Blood Sugar Control Compared With Oral Semaglutide - Drug Topics

Orforglipron Demonstrates Superior Blood Sugar Control Compared With Oral Semaglutide Drug Topics

Novo to knock down Ozempic, Wegovy list prices next year, but self-pay channels unaffected - Fierce Pharma

Novo to knock down Ozempic, Wegovy list prices next year, but self-pay channels unaffected Fierce Pharma

FDA and Novo Nordisk Warn of GLP-1 Telehealth Compounding Take Down – What’s Next? - Spencer Fane

FDA and Novo Nordisk Warn of GLP-1 Telehealth Compounding Take Down – What’s Next? Spencer Fane

Orforglipron offers greater weight loss for people with diabetes than oral semaglutide - The Pharmaceutical Journal

Orforglipron offers greater weight loss for people with diabetes than oral semaglutide The Pharmaceutical Journal

Novo Nordisk slashing prices for weight-loss and diabetes drugs Ozempic, Wegovy and Rybelsus - The Hill

Novo Nordisk slashing prices for weight-loss and diabetes drugs Ozempic, Wegovy and Rybelsus The Hill

Novo Nordisk Gains European Approval for Semaglutide 7.2 mg, Submits Application to FDA - HCPLive

Novo Nordisk Gains European Approval for Semaglutide 7.2 mg, Submits Application to FDA HCPLive

Why Scientists Are Urging Caution About a Common Ingredient in Semaglutide and Ozempic - SciTechDaily

Why Scientists Are Urging Caution About a Common Ingredient in Semaglutide and Ozempic SciTechDaily

Orforglipron Outperforms Oral Semaglutide in Head-to-Head Type 2 Diabetes Trial - The American Journal of Managed Care® (AJMC®)

Orforglipron Outperforms Oral Semaglutide in Head-to-Head Type 2 Diabetes Trial The American Journal of Managed Care® (AJMC®)

Lilly's oral GLP-1 orforglipron bests oral semaglutide - The Pharma Letter

Lilly's oral GLP-1 orforglipron bests oral semaglutide The Pharma Letter

New High-Dose Semaglutide: The Future of Weight Loss? - HCPLive

New High-Dose Semaglutide: The Future of Weight Loss? HCPLive

Higher dose of semaglutide increases weight loss, metabolic benefits: Newsroom - UT Southwestern

Higher dose of semaglutide increases weight loss, metabolic benefits: Newsroom UT Southwestern

Zydus set for Day 1 launch of semaglutide generic with reusable multi-dose pen - ET Pharma

Zydus set for Day 1 launch of semaglutide generic with reusable multi-dose pen ET Pharma

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity | New England Journal of Medicine - The New England Journal of Medicine

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity | New England Journal of Medicine The New England Journal of Medicine

Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice - Nature

Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice Nature

Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say - The Economic Times

Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say The Economic Times

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial - The Lancet

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial The Lancet